NCT03171714

Brief Summary

In this research study, a device called the Derma-Stent will be tested. The sponsor of the study, Mar-Med Company, will supply the device. This device is used to drain a cutaneous abscess, which is a skin infection that results in buildup of pus under the skin. Currently, the normal treatment for this abscess is to cut and drain and the wound, and later pack the wound with gauze. Packing is done to prevent the pus to accumulate again. But regular gauze is difficult for patient to remove themselves, so another visit to the doctor is usually necessary. The Derma-Stent device will be tested to see how easily patients can remove this by themselves and if it is less painful and more effective than normal gauze packing.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P75+ for phase_1

Timeline
Completed

Started Mar 2017

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 27, 2017

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

May 26, 2017

Completed
5 days until next milestone

First Posted

Study publicly available on registry

May 31, 2017

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 30, 2017

Completed
15 days until next milestone

Study Completion

Last participant's last visit for all outcomes

December 15, 2017

Completed
Last Updated

June 8, 2017

Status Verified

June 1, 2017

Enrollment Period

8 months

First QC Date

May 26, 2017

Last Update Submit

June 6, 2017

Conditions

Keywords

Drainage Catheter

Outcome Measures

Primary Outcomes (1)

  • Likelihood of self removal

    Likelihood of self removal, as measured on a 1-10 Likert scale.

    3-5 days

Secondary Outcomes (4)

  • Clinical Failure Rate

    32 days after baseline

  • Recurrence Rate of Abscess

    3-5 day and one month follow-up

  • Cosmetic Result

    3-5 day and one month

  • Pain during procedure and packing removal

    baseline and 3-5 day

Study Arms (2)

Derma-Stent

EXPERIMENTAL

The novel silicon packing device made of a nonabsorbent material to pack a drained abscess for healing.

Device: Derma-Stent

Usual Care, cotton gauze packing

ACTIVE COMPARATOR

Standard of care to pack a drained abscess for healing.

Device: Usual care, cotton gauze packing

Interventions

The novel device will facilitate self removal by patients, as it has a narrower profile, and, as a nonabsorbent material, will not become saturated with bodily fluids. Although it will not absorb body fluids

Derma-Stent

Standard gauze packing used to pack a drained abscess.

Usual Care, cotton gauze packing

Eligibility Criteria

Age18 Years - 90 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • ED patient \> 18, \< 90.
  • Abscess total dimensions (z+y+z) by ultrasound greater or equal to 5 cm.
  • Consent to participate in research protocol.
  • Assessment by attending physician that the abscess will require packing.

You may not qualify if:

  • Patients requiring admission for skin and soft tissue infection.
  • Abscess drainage requiring procedural sedation.
  • Abscesses requiring incision and drainage in the operating room.
  • Inability to comprehend consent and follow up instructions.
  • Prisoners.
  • Pregnant women.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Wayne State University

Detroit, Michigan, 48201, United States

RECRUITING

Related Publications (6)

  • Pallin DJ, Egan DJ, Pelletier AJ, Espinola JA, Hooper DC, Camargo CA Jr. Increased US emergency department visits for skin and soft tissue infections, and changes in antibiotic choices, during the emergence of community-associated methicillin-resistant Staphylococcus aureus. Ann Emerg Med. 2008 Mar;51(3):291-8. doi: 10.1016/j.annemergmed.2007.12.004. Epub 2008 Jan 28.

    PMID: 18222564BACKGROUND
  • Qualls ML, Mooney MM, Camargo CA Jr, Zucconi T, Hooper DC, Pallin DJ. Emergency department visit rates for abscess versus other skin infections during the emergence of community-associated methicillin-resistant Staphylococcus aureus, 1997-2007. Clin Infect Dis. 2012 Jul;55(1):103-5. doi: 10.1093/cid/cis342. Epub 2012 Mar 28.

    PMID: 22460965BACKGROUND
  • Singer AJ, Talan DA. Management of skin abscesses in the era of methicillin-resistant Staphylococcus aureus. N Engl J Med. 2014 Mar 13;370(11):1039-47. doi: 10.1056/NEJMra1212788. No abstract available.

    PMID: 24620867BACKGROUND
  • Tsoraides SS, Pearl RH, Stanfill AB, Wallace LJ, Vegunta RK. Incision and loop drainage: a minimally invasive technique for subcutaneous abscess management in children. J Pediatr Surg. 2010 Mar;45(3):606-9. doi: 10.1016/j.jpedsurg.2009.06.013.

    PMID: 20223328BACKGROUND
  • Ladd AP, Levy MS, Quilty J. Minimally invasive technique in treatment of complex, subcutaneous abscesses in children. J Pediatr Surg. 2010 Jul;45(7):1562-6. doi: 10.1016/j.jpedsurg.2010.03.025.

    PMID: 20638546BACKGROUND
  • Gaszynski R, Punch G, Verschuer K. Loop and drain technique for subcutaneous abscess: a safe minimally invasive procedure in an adult population. ANZ J Surg. 2018 Jan;88(1-2):87-90. doi: 10.1111/ans.13709. Epub 2016 Sep 12.

    PMID: 27621209BACKGROUND

Study Officials

  • Aaron Brody, MD, MPH

    Wayne State University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Phase 1 - Pilot Trial: As this device has never been used on humans, the investigators will first deploy a pilot, uncontrolled trial of 10 subjects to assess for safety, and further refine outcome measures. The same protocol will be followed as the controlled trial, except the randomization. Phase 2 - Controlled Trial: 25 patients in each arm: 1. Novel silicon packing device 2. Usual Care, cotton gauze packing
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

May 26, 2017

First Posted

May 31, 2017

Study Start

March 27, 2017

Primary Completion

November 30, 2017

Study Completion

December 15, 2017

Last Updated

June 8, 2017

Record last verified: 2017-06

Data Sharing

IPD Sharing
Will not share

Locations